![5000100-flag[1].jpg](https://cdn.european-virus-archive.com/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
Check our latest paper @LancetMicrobe with @scarsett84 @Ribeirocds @amberhscholz and @EVAg_EU community. Our data shows that during global pandemics, EVA distributed materials to 112 countries! #BenefitSharing #Biobanks #COVID19 https://t.co/eLsQdbCYFk
Back to "real" conferences ! EVA will host a booth at the French Plant Virology meeting next week. We offer 90 products related to plant viruses on our catalogue: viruses, derived products and services. Here: #RRV2021'>#RRV2021'>https://t.co/VjqZTcIvCl #RRV2021'>#RRV2021 @INRAE_PV @PHIM_research @SFP_France https://t.co/xGtZbpmPza
The latest SARS-CoV-2 variant is now ready for orders : 20A/452R (B.1.617), Germany ex India @rki_de'>@rki_de'>https://t.co/jwMAVY4sBo @rki_de'>@rki_de https://t.co/cZIIiDkvpW
A nice paper illustrating the role EVA played for Iran at the very beginning of the SARS-CoV-2 pandemic. #EVAg_EU #H2020 https://t.co/eJaB6VaP7A https://t.co/i7Rlu4Jdbx
Come and talk to us until 6pm to learn about the importance of biobanking as a preparedness tool against viral emergence ! Here at Journée Francophones de Virologie: https://t.co/KAiXQpcSpk
Our SARS-CoV-2 subcollection is still growing. 43 strains, with new additions today https://t.co/gdiE6FFfRp
In the next few days, we will add other SARS-CoV-2 variants to our catalogue: "Brazil" P.1, "Brazil" P2, B.1.429+L452R ("California" variant). Find them here when they're ready for orders: @EU_H2020'>@EU_H2020'>https://t.co/9HDBB5nNPR @EU_H2020'>@EU_H2020 https://t.co/SjncIe6SyC
This section is dedicated to preclinical evaluation of molecules with antiviral potential against the SARS-CoV-2. It may receive links to important pu... read more
The EVA-GLOBAL community supports fair and equitable benefit sharing as conceived in various United Nations frameworks. The consortium is actively imp... read more
Our lab detected first coastal Kenya COVID-19 positive cases using EVA primers. This has allowed aggressive contact tracing and case isolation. Now were are key contributors in diagnostics in the Kenya and obtaining more diagnostic kits will go a long way in supporting local and national COVID-19 response plan.
Thank you so much! The package already arrived - I am amazed. We have so much problems with the primers and probes - some did not work, some were contaminated. Your ones are the only ones which work perfectly in our hands now. With your delivery, we can go on and meanwhile try to test additional providers.
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
